Processa Pharmaceuticals, Inc.
PCSA
$1.99
-$0.17-7.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.69M | 1.52M | 1.59M | 1.83M | 1.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.34M | 3.33M | 3.70M | 3.49M | 3.95M |
| Operating Income | -2.34M | -3.33M | -3.70M | -3.49M | -3.95M |
| Income Before Tax | -3.27M | -3.38M | -3.36M | -3.44M | -3.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.27M | -3.38M | -3.36M | -3.44M | -3.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.27M | -3.38M | -3.36M | -3.44M | -3.93M |
| EBIT | -2.34M | -3.33M | -3.70M | -3.49M | -3.95M |
| EBITDA | -2.34M | -3.33M | -3.70M | -3.49M | -3.95M |
| EPS Basic | -1.19 | -1.29 | -1.49 | -1.81 | -6.26 |
| Normalized Basic EPS | -0.74 | -0.80 | -0.93 | -1.13 | -3.91 |
| EPS Diluted | -1.19 | -1.29 | -1.49 | -1.81 | -6.26 |
| Normalized Diluted EPS | -0.74 | -0.80 | -0.93 | -1.13 | -3.91 |
| Average Basic Shares Outstanding | 2.75M | 2.62M | 2.26M | 1.90M | 628.80K |
| Average Diluted Shares Outstanding | 2.75M | 2.62M | 2.26M | 1.90M | 628.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |